DrugImproverGPT: A Large Language Model for Drug Optimization with Fine-Tuning via Structured Policy Optimization

• URL: http://arxiv.org/abs/2502.07237v1
• Date: Tue, 11 Feb 2025 04:00:21 GMT
• Title: DrugImproverGPT: A Large Language Model for Drug Optimization with Fine-Tuning via Structured Policy Optimization
• Authors: Xuefeng Liu, Songhao Jiang, Siyu Chen, Zhuoran Yang, Yuxin Chen, Ian Foster, Rick Stevens,
• Abstract summary: Finetuning a Large Language Model (LLM) is crucial for generating results towards specific objectives. This research introduces a novel reinforcement learning algorithm to finetune a drug optimization LLM-based generative model.
• Score: 53.27954325490941
• License:
• Abstract: Finetuning a Large Language Model (LLM) is crucial for generating results towards specific objectives. This research delves into the realm of drug optimization and introduce a novel reinforcement learning algorithm to finetune a drug optimization LLM-based generative model, enhancing the original drug across target objectives, while retains the beneficial chemical properties of the original drug. This work is comprised of two primary components: (1) DrugImprover: A framework tailored for improving robustness and efficiency in drug optimization. It includes a LLM designed for drug optimization and a novel Structured Policy Optimization (SPO) algorithm, which is theoretically grounded. This algorithm offers a unique perspective for fine-tuning the LLM-based generative model by aligning the improvement of the generated molecule with the input molecule under desired objectives. (2) A dataset of 1 million compounds, each with OEDOCK docking scores on 5 human proteins associated with cancer cells and 24 binding sites from SARS-CoV-2 virus. We conduct a comprehensive evaluation of SPO and demonstrate its effectiveness in improving the original drug across target properties. Our code and dataset will be publicly available at: https://github.com/xuefeng-cs/DrugImproverGPT.

Related papers

• ScaffoldGPT: A Scaffold-based Large Language Model for Drug Improvement [2.6198448284771443]
  ScaffoldGPT is a novel Large Language Model (LLM) designed for drug optimization based on molecular scaffolds. Our work comprises three key components: (1) A three-stage drug optimization approach that integrates pretraining, finetuning, and decoding optimization.
  arXiv  Detail & Related papers  (2025-02-09T10:36:33Z)
• GramSeq-DTA: A grammar-based drug-target affinity prediction approach fusing gene expression information [1.2289361708127877]
  We propose GramSeq-DTA, which integrates chemical perturbation information with the structural information of drugs and targets. Our approach outperforms the current state-of-the-art DTA prediction models when validated on widely used DTA datasets.
  arXiv  Detail & Related papers  (2024-11-03T03:17:09Z)
• Decomposed Direct Preference Optimization for Structure-Based Drug Design [47.561983733291804]
  We propose DecompDPO, a structure-based optimization method to align diffusion models with pharmaceutical needs. DecompDPO can be effectively used for two main purposes: fine-tuning pretrained diffusion models for molecule generation across various protein families, and molecular optimization given a specific protein subpocket after generation.
  arXiv  Detail & Related papers  (2024-07-19T02:12:25Z)
• Aligning Target-Aware Molecule Diffusion Models with Exact Energy Optimization [147.7899503829411]
  AliDiff is a novel framework to align pretrained target diffusion models with preferred functional properties. It can generate molecules with state-of-the-art binding energies with up to -7.07 Avg. Vina Score.
  arXiv  Detail & Related papers  (2024-07-01T06:10:29Z)
• Improving Targeted Molecule Generation through Language Model Fine-Tuning Via Reinforcement Learning [0.0]
  We introduce an innovative de-novo drug design strategy, which harnesses the capabilities of language models to devise targeted drugs for specific proteins. Our method integrates a composite reward function, combining considerations of drug-target interaction and molecular validity.
  arXiv  Detail & Related papers  (2024-05-10T22:19:12Z)
• DecompOpt: Controllable and Decomposed Diffusion Models for Structure-based Molecular Optimization [49.85944390503957]
  DecompOpt is a structure-based molecular optimization method based on a controllable and diffusion model. We show that DecompOpt can efficiently generate molecules with improved properties than strong de novo baselines.
  arXiv  Detail & Related papers  (2024-03-07T02:53:40Z)
• DrugAssist: A Large Language Model for Molecule Optimization [29.95488215594247]
  DrugAssist is an interactive molecule optimization model that performs optimization through human-machine dialogue. DrugAssist has achieved leading results in both single and multiple property optimization. We publicly release a large instruction-based dataset called MolOpt-Instructions for fine-tuning language models on molecule optimization tasks.
  arXiv  Detail & Related papers  (2023-12-28T10:46:56Z)
• Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning [82.93806087715507]
  Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation. Deep learning models have emerged as an efficient way to discover synergistic combinations. Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
  arXiv  Detail & Related papers  (2023-01-14T15:07:43Z)
• Tailoring Molecules for Protein Pockets: a Transformer-based Generative Solution for Structured-based Drug Design [133.1268990638971]
  De novo drug design based on the structure of a target protein can provide novel drug candidates. We present a generative solution named TamGent that can directly generate candidate drugs from scratch for a given target.
  arXiv  Detail & Related papers  (2022-08-30T09:32:39Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.